Relapsed High-Risk Medulloblastoma: Stable Disease after Two Years of Treatment with Somatostatin Analog - Case Report
Luisa Galvis, Diego Gonzalez, Carlos Bonilla, Luisa Galvis, Diego Gonzalez, Carlos Bonilla
Abstract
Cerebellar medulloblastoma in adults is an uncommon disease. Therefore, most information comes from the pediatric population, and the treatment for relapses is based on series and case reports. The expression of somatostatin receptors has been identified in most medulloblastoma patients, and preclinical experience has shown a promissory response to somatostatin analogs. This report presents a female patient with a high-risk left cerebellar medulloblastoma diagnosed at age 16 years old who was treated with complete resection, cranial-spinal radiotherapy, and chemotherapy. She presented again at 18 years of age with a sustained progression of her tumor, despite radiosurgery and another line of chemotherapy. Octreotide scintigraphy at that time showed a moderate to high expression of somatostatin receptors; thus, the patient was started on monthly octreotide. She is now 20 and has achieved stable disease over more than two years of active treatment without any drug-related toxicity. Somatostatin analogs could be considered as a treatment option in selected cases of medulloblastoma. Review of the literature is presented for this unusual response.
Keywords: medulloblastoma; octreotide; somatostatin.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
References
- Brandes AA, Bartolotti M, Marucci G, Ghimenton C, Agati R, Fioravanti A, Mascarin M, Volpin L, Ammannati F, Masotto B, Gardiman MP, De Biase D, Tallini G, Crisi G, Bartolini S, Franceschi E. Crit Rev Oncol Hematol. Vol. 94. Jun: 2015. New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology; pp. 348–359.
- An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Chang CH, Housepian EM, Herbert C Jr. Radiology. 1969;93:1351–1359.
- The clinical implications of medulloblastoma subgroups. Northcott PA, Korshunov A, Pfister SM, Taylor MD. Nat Rev Neurol. 2012;8:340–351.
- Chemotherapy for children with medulloblastoma. [Nov;2015 ];Michiels EMC, Schouten-Van Meeteren AYN, Doz F, Janssens GO, van Dalen EC. Cochrane Database Syst Rev. 2015 1:0.
- Adult medulloblastoma: Prognostic factors and response to therapy at diagnosis and at relapse. Herrlinger U, Steinbrecher A, Rieger J, Hau P, Kortmann RD, Meyermann R, Schabet M, Bamberg M, Dichgans J, Bogdahn U, Weller M. J Neurol. 2005;252:291–299.
- Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: A pediatric brain tumor consortium study. Gajjar A, Stewart CF, Ellison DW, Kaste S, Kun LE, Packer RJ, Goldman S, Chintagumpala M, Wallace D, Takebe N, Boyett JM, Gilbertson RJ, Curran T. Clin Cancer Res. 2013;19:6305–6312.
- Somatostatin receptor subtype 2 (sst₂) is a potential prognostic marker and a therapeutic target in medulloblastoma. Remke M, Hering E, Gerber NU, Kool M, Sturm D, Rickert CH, Gerß J, Schulz S, Hielscher T, Hasselblatt M, Jeibmann A, Hans V, Ramaswamy V, Taylor MD, Pietsch T, Rutkowski S, Korshunov A, Monoranu CM, Frühwald MC. Childs Nerv Syst. 2013;29:1253–1262.
- High expression of somatostatin receptor subtype 2 (sst2) in medulloblastoma: implications for diagnosis and therapy. Frühwald MC, O'Dorisio MS, Pietsch T, Reubi JC. Pediatr Res. 1999;45:697–708.
- Octreotide in the therapy of recurrent medulloblastomas. Stefanović I, Stojanović N, Stojanov D, Dimov D. Arch Oncol. 2006;14:26–29.
- Complete response after treatment with a somatostatin analogue in an adult patient with recurrent medulloblastoma. Glas M, Hennemann B, Hirschmann B, Marienhagen J, Schmidt-Wolf I, Herrlinger U, Bogdahn U, Hau P. Acta Oncol. 2008;47:479–480.
Source: PubMed